Observational study of type of surgical training and outcome of definitive surgery for primary malignant melanoma by Mackie, R.M. et al.
and Lynettte Yaxley for help in initial development of the study
and Michael Grande for statistical advice. RCT is guarantor for
the study.
Funding: None.
Competing interests: None declared.
1 Casson IF, Clarke CA, Howard CV, McKendrick O, Pennycook S, Pharoah
POD, et al. Outcomes of pregnancy in insulin dependent women: results
of a five year cohort study. BMJ 1997;315:275›8.
2 Hawthorne G, Robson S, Ryall EA, Sen D, Roberts SH, Ward Platt MP.
Prospective population based survey of outcome of pregnancy in diabetic
women: results of the northern diabetic pregnancy audit, 1994. BMJ
1997;315:279›81.
3 Hanson U, Persson B, Thurnell S. Relationship between haemoglobin
A1c in early type 1 (insulin›dependent) diabetic pregnancy and the
occurrence of spontaneous abortion and fetal malformation in Sweden.
Diabetologia 1990;33:100›4.
4 Nielson GL, Sorensen PH, Nielson PH, Sabroe S, Olsen J. Glycosylated
hemoglobin as predictor of adverse fetal outcome in type 1 diabetic
pregnancies. Acta Diabetol 1997;34:217›22.
5 Rosenn B, Miodovnik M, Combs CA, Khoury J, Siddiqi TA. Glycaemic
thresholds for spontaneous abortions and congenital malformations in
insulin›dependent diabetes mellitus. Obstet Gynecol 1994;84:515›20.
(Accepted 22 April 2002)
Observational study of type of surgical training
and outcome of definitive surgery for primary
malignant melanoma
Rona M MacKie, Caroline A Bray, David J Hole
The incidence of primary cutaneous malignant
melanoma continues to rise,1 coinciding with narrower
excision margins of normal skin being recommended
around primary melanomas.2 3 The bulk of surgery for
primary melanoma is now done on an outpatient basis
under local anaesthesia. This change has occurred at a
time when training in dermatological surgery has
developed, leading to a much higher proportion of
excisions of primary melanoma being done by derma›
tologists. In 1979 in the west of Scotland only 3% of all
primary melanomas were removed by dermatologists.
By 1998 this figure had risen to 40%. Plastic surgeons
now excise 26% of primary melanomas compared with
65% 20 years ago, and general surgeons excise 34%
compared with 32%.
We aimed to establish if the change in type of sur›
geon removing primary cutaneous malignant
melanoma has affected the prognosis, and also
whether any evidence exists for a specialist treatment
effect such as has been observed for breast cancers,
with better outcomes for surgeons carrying out breast
cancer surgery regularly.4
Participants, methods, and results
We identified 4159 melanoma patients from the files of
the Scottish melanoma group. All patients had had
their primary melanoma removed between 1979 and
1998. We divided the surgeons performing the defini›
tive excision of the primary melanoma into dermato›
logical, plastic surgery, or general surgery training. We
recorded age, sex, tumour thickness, presence of
ulceration, and maximum diameter of the primary
tumour and noted mortality and cause of death up to
1998. We also looked at the effect within the three sur›
gical groups of treating up to six or more than six pri›
mary melanomas annually.
An average of 10 years’ follow up information was
available for all patients. To test for an association
between tumour thickness and type of surgical
experience we used the ÷2 statistic for trend, aggregated
over the period of diagnosis. We used the Cox
proportional hazards model to compare the survival of
patients in relation to surgical experience,5 with
adjustment for thickness, ulceration, and maximum
diameter of tumour and sex, age, and deprivation
category of patients.
The table shows the division of patients by tumour
thickness, ulceration, maximum diameter of primary
melanoma, and outcome by surgical training. Derma›
tologists treated a significantly higher proportion of
thin melanomas (P < 0.001). The proportion of
ulcerated melanomas was higher in the plastic surgery
group than in the dermatological group (P < 0.001)
and higher in the general surgical group than the
plastic surgery group (P < 0.001).
After adjustment for thickness, the best outcome
was in the dermatological surgeon treatment group
Details of melanomas treated, by surgical groups adjusted for type of surgical training. Values are numbers (percentages) unless stated otherwise
Characteristics of melanomas Dermatologist surgeon (n=1076) Plastic surgeon (n=1691) General surgeon (n=1392) Total (n=4159)
Primary tumours <1.5 mm thick 739 (69)* 809 (48) 589 (42) 2137 (51)
Primary tumours 1.5›3.49 mm thick 217 (20) 447 (26) 342 (25) 1006 (24)
Primary tumours >3.5 mm thick 120 (11) 435 (26) 461 (33) 1016 (24)
No of primary tumours ulcerated 129 (12)* 432 (26)* 499 (36) 1060 (25)
Relative hazard ratios† (95% CI) (risk of death)
Adjusted for thickness‡ 1.0 1.33 (1.07 to 1.65) 1.41 (1.14 to 1.75) P=0.008
Adjusted for thickness and ulceration 1.0 1.22 (0.97 to 1.54) 1.23 (0.97 to 1.55) P=0.19
Adjusted for thickness, ulceration, and maximum diameter 1.0 1.14 (0.88 to 1.48) 1.18 (0.90 to 1.54) P=0.48
*P<0.001 for comparison of proportion of thin melanomas treated by dermatological surgeons compared with other surgeons; also for proportion of ulcerated melanomas both between
dermatological and plastic surgeons and between plastic and general surgeons.
†Sex, age, deprivation category, and year of diagnosis were considered in the model but did not contribute any significant impact on surgical training differences.
‡Thickness of primary tumour has been entered as a stratification variable owing to non›proportionality of the hazard functions.
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(P=0.008). Statistical significance was lost when adjust›
ment was made for ulceration and then for maximum
diameter. We found no evidence that surgeons in any
of the three categories who performed more than six
primary melanoma excisions annually had better
outcomes than those who performed fewer excisions.
Comment
Survival of melanoma patients does not depend on the
surgical background of the person removing the
primary tumour. The object of this study was to
provide an evidence base for primary care guidelines
on appropriate specialist referral. The data show that
the growth in dermatological surgeons excising
primary melanomas has had no adverse affect on
patient outcome. We found no evidence that any type
of surgeon performing excisions of primary melano›
mas regularly had a better outcome than those who
carried out fewer excisions, possibly because wide local
excision is a relatively simple procedure. We therefore
provide an evidence base to recommend referral of
suspected primary melanomas to the dermatological,
plastic surgery, or general surgical service with the
shortest surgical waiting time.
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Drug points
Dysgeusia and burning mouth syndrome by
eprosartan
Xavier Castells, Isidre Rodoreda, Consuelo Pedrós, Gloria Cereza,
Joan›Ramon Laporte
Eprosartan is an angiotensin II receptor antagonist.
Dysgeusia and burning mouth syndrome attributed to
angiotensin converting enzyme inhibitors have been
reported.1 Several case reports related to angiotensin II
receptor antagonists have also been published. We report
the case of a patient in whom oral eprosartan induced
reversible taste disturbance and burning mouth sensation
on two occasions. This case was reported to the Catalan
pharmacovigilance centre.
A 48 year old woman with a 10 year history of essen›
tial hypertension was being treated with valsartan 160 mg
daily. She had no other medical condition and was not
taking any other drugs. She started taking eprosartan
600 mg daily because her blood pressure remained
uncontrolled with valsartan. Three weeks later she
complained of a metallic taste and a burning sensation in
her mouth. The oral cavity was normal and no underlying
medical causes were identified. She stopped taking
eprosartan and one week later her taste had returned to
normal. The dysgeusia was not attributed to eprosartan
and she started taking the drug again. A few days later,
dysgeusia and the burning sensation in her mouth
returned. She stopped taking eprosartan and her taste
recovered in two days.
Taste disorders related to angiotensin II receptor
antagonists had not been described in clinical trials,2 but
several cases of dysgeusia have been reported in patients
treated with losartan3–5 and with valsartan.6 To our knowl›
edge, this is the first reported case of dysgeusia induced by
eprosartan and the first case of dysgeusia induced by
angiotensin II receptor antagonists with positive rechal›
lenge. Dysgeusia with losartan but not with angiotensin
converting enzyme inhibitors has been reported to occur
in the same patient, suggesting that angiotensin convert›
ing enzyme inhibitors or angiotensin II receptor
antagonists produce this effect by acting through different
mechanisms.5 Because the incidence of dysgeusia in
patients treated with drugs from these two therapeutic
groups is low,1 2 it is possible that this adverse effect
appears only in patients with some predisposing
condition.
In our case report, the temporal sequence of events—
and, in particular, positive rechallenge—and the lack of
underlying concomitant diseases or other drugs strongly
suggest that the association between dysgeusia, burning
mouth syndrome, and eprosartan was causal. Because
these effects occurred with eprosartan but not with valsar›
tan at equivalent doses, however, our observation does not
favour the theory of an effect due to the angiotensin II
receptor antagonist class of drug. Factors predisposing to
this adverse effect remain to be identified and the
mechanism remains to be elucidated.
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